Condition

HER2 Positive Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting2
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyNCT06958627 · 2024-04-30
RECRUITING
Pre Operative Trastuzumab in Operable Breast CancerNCT01785420 · 2013-05-01
RECRUITING
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment CyclesNCT06868017 · 2025-04-01
NOT_YET_RECRUITING
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · 2022-08-31
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07
ACTIVE_NOT_RECRUITING
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · 2020-12-01
COMPLETED
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.NCT03947242 · 2019-06-01
UNKNOWN
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.NCT03735966 · 2018-11-20
COMPLETED
Adapted Physical Activity for Breast Cancer HER2 Positive PatientNCT02963363 · 2018-04-27
TERMINATED
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer PatientsNCT03013504 · 2018-02-19
COMPLETED
Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · 2017-02-13
COMPLETED
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)NCT02705859 · 2016-04-01
COMPLETED
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerNCT02614794 · 2016-01-28
COMPLETED
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast CancerNCT02476539 · 2015-10-14
COMPLETED
A Prospective Study of Breast Cancer Patients With Abnormal Strain ImagingNCT02993198 · 2015-04-01
UNKNOWN
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast CancerNCT02362958 · 2015-01-09
COMPLETED
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)NCT02125344 · 2014-12-01
COMPLETED
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsNCT02213744 · 2014-07-01
TERMINATED
Cardiac Safety Study in Patients With HER2 + Breast CancerNCT01904903 · 2013-10-01
COMPLETED
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast CancerNCT01840306 · 2012-10-12
COMPLETED
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerNCT00817362 · 2009-03-01
TERMINATED

Common interventions

trastuzumabDRUG9PertuzumabDRUG4CyclophosphamideDRUG3EpirubicinDRUG3PlaceboDRUG3TucatinibDRUG3capecitabineDRUG2CarboplatinDRUG2Ado Trastuzumab EmtansineDRUG1Biomarker AnalysisOTHER1CarvedilolDRUG1Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 dosesDRUG1Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 dosesDRUG1ColesevelamDRUG1Combination product: Trastuzumab + PertuzumabDRUG1CopanlisibDRUG1DenosumabDRUG1DocetaxelDRUG1Ferric carboxymaltoseDRUG1GemcitabineDRUG1HD201DRUG1Hemay022DRUG1HerceptinDRUG1Home-based Adapted Physical ActivityOTHER1IPI-504DRUG1

Trial status mix

COMPLETED11
TERMINATED3
ACTIVE_NOT_RECRUITING2
RECRUITING2
UNKNOWN2
NOT_YET_RECRUITING1

Phase mix

PHASE211
PHASE36
NA2
PHASE12
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.